Cover Image

Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective

Naoky Tsai,1 Lennox Jeffers,2 Lael Cragin,3 Sonja Sorensen,3 Wenqing Su,3 Lisa Rosenblatt,4 Hong Tang,4 Tony Hebden,4 Timothy Juday41John A Burns School of Medicine, University of Hawaii, Honolulu, HI, USA; 2University of Miami School of Medicine, Miami, FL, USA; 3United BioSource Corporation, Bethe...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tsai N (Author), Jeffers L (Author), Cragin L (Author), Sorensen S (Author), Su W (Author), Rosenblatt L (Author), Tang H (Author), Hebden T (Author), Juday T (Author)
Format:	Book
Published:	Dove Medical Press, 2012-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance
by: Wang G, et al.
Published: (2015)

Plasmatic and intracellular concentration of entecavir during treatment of a symptomatic flare in HBV-HDV decompensated cirrhosis
by: Ilaria De Benedetto, et al.
Published: (2020)

Cost of illness of chronic kidney disease in Lebanon: from the societal and third-party payer perspectives
by: Mabel Aoun, et al.
Published: (2022)

Correction: Cost of illness of chronic kidney disease in Lebanon: from the societal and third-party payer perspectives
by: Mabel Aoun, et al.
Published: (2022)

Induced Rhabdomyolysis Associated With Decompensated Cirrhosis
by: William Dungan MD, et al.
Published: (2022)

Retrospective Analysis and Forecasted Economic Impact of a Virtual Cardiac Rehabilitation Program in a Third-Party Payer Environment
by: Arash Harzand, et al.
Published: (2021)

A bite difficult to heal: Pasteurella multocida induced decompensated hepatic cirrhosis
by: Hiren Patel, et al.
Published: (2021)

Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety
by: Kelly L. Hayward, et al.
Published: (2021)

Buschke-Lowenstein tumor in a patient with decompensated cirrhosis
by: F. N. U. Shailesh, et al.
Published: (2014)

Cryptococcemia in an HIV-negative patient with decompensated liver cirrhosis
by: Manasa Kandula, et al.
Published: (2016)

Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System
by: Renjun Yang, et al.
Published: (2022)

Comparative effectiveness of tenofovir versus entecavir in patients with hepatitis B virus-related cirrhosis in Taiwan: a retrospective cohort study
by: Yu-Han Huang, et al.
Published: (2023)

Sarcopenia and frailty combined increases the risk of mortality in patients with decompensated cirrhosis
by: Gaoyue Guo, et al.
Published: (2022)

Analysis of hope level and its influencing factors in patients with decompensated cirrhosis
by: Yuanyuan Zhang, et al.
Published: (2023)

Association Between Nonselective Beta-Blocker Use and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Without Cirrhosis and Decompensation
by: He-Yun Cheng, et al.
Published: (2022)

Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores
by: Yan Huang, et al.
Published: (2022)

Characteristic of renal response to the salt-loading test in patients with decompensated liver cirrhosis
by: O. B. Kvasnytska, et al.
Published: (2018)

Characteristic of renal response to the salt-loading test in patients with decompensated liver cirrhosis
by: O. B. Kvasnytska, et al.
Published: (2018)

Cost-effectiveness of albumin in the treatment of decompensated cirrhosis in resource-limited healthcare settings
by: Irsan Hasan, et al.
Published: (2024)

Fecal Microbiota Transplantation in Decompensated Cirrhosis: A Systematic Review on Safety and Efficacy
by: Annie S. Hong, et al.
Published: (2022)

Association between serum trace elements and sleep disturbance in patients with decompensated cirrhosis
by: Ziyue Zhang, et al.
Published: (2023)

The characteristic of a splanchnic blood-groove at patients with the compensated and decompensated course of cirrhosis
by: A. S. Tugushev, et al.
Published: (2015)

Impact of sarcopenia on the survival of patients undergoing liver transplantation for decompensated liver cirrhosis
by: Da Zhou, et al.
Published: (2023)

The treatment of chronic hepatitis B: Focus on adefovir-like antivirals
by: Hans Ludger Tillmann
Published: (2008)

The Role of Clinical Pharmacist in Reducing Drug Related Problems in Decompensated Liver cirrhosis patients
by: Ameer Alobeidi, et al.
Published: (2023)

Decreased overall mortality rate with Chinese herbal medicine usage in patients with decompensated liver cirrhosis in Taiwan
by: Fuu-Jen Tsai, et al.
Published: (2020)

Voltammetric quantification of anti-hepatitis drug Adefovir in biological matrix and pharmaceutical formulation
by: Rajeev Jain, et al.
Published: (2012)

Clinical utility of entecavir for chronic hepatitis B in Chinese patients
by: Wang JY
Published: (2013)

Nonlinear Relationship Between Macrocytic Anemia and Decompensated Hepatitis B Virus Associated Cirrhosis: A Population-Based Cross-Sectional Study
by: Tian-Yu Zhao, et al.
Published: (2021)

Association of Systemic Inflammation Response Index with Short-Term All-Cause Mortality in Decompensated Liver Cirrhosis Patients
by: Cheng J, et al.
Published: (2024)

Entecavir Treatment in Children and Adolescents with Chronic Hepatitis B Virus Infection
by: Kai-Chi Chang, et al.
Published: (2016)

Clinical features of hypophosphatemic osteomalacia induced by long-term low-dose adefovir dipivoxil
by: Zhu S, et al.
Published: (2017)

Low-dose adefovir dipivoxil–induced hypophosphatemia osteomalacia in five chronic hepatitis B virus–infected patients. Is low-dose adefovir dipivoxil–induced nephrotoxicity completely reversible?
by: Qian YY, et al.
Published: (2019)

Cost-effectiveness of overactive bladder treatments from a US commercial and payer perspective
by: Brian Murray, et al.
Published: (2023)

Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy
by: Huang M, et al.
Published: (2019)

Urinary albumin-to-creatinine ratio in decompensated liver cirrhosis among elderly Egyptian patients: a single-center experience
by: Ahmed Abdelghani, et al.
Published: (2021)

The performance of third-party funds, consumption credit and profitability
by: Herry Achmad Buchory, et al.
Published: (2022)

COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status
by: Zhujun Cao, et al.
Published: (2022)

Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients
by: Zhang C, et al.
Published: (2016)

Constipation during Entecavir treatment in Chronic Hepatitis B patients: Two Cases Reports
by: Meng-Lan Wang, et al.
Published: (2017)